ECOR logo

electroCore Stock Price

Symbol: NasdaqCM:ECORMarket Cap: US$50.5mCategory: Healthcare

ECOR Share Price Performance

US$7.25
1.50 (26.09%)
65.6% undervalued intrinsic discount
US$21.10
Fair Value
US$7.25
1.50 (26.09%)
65.6% undervalued intrinsic discount
US$21.10
Fair Value
Price US$7.25
AnalystConsensusTarget US$21.10

ECOR Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget·Updated
Fair Value US$21.10 65.6% undervalued intrinsic discount

Quell, gammaCore And Truvaga Will Expand US And Global Markets

0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative

Recent ECOR News & Updates

No updates

electroCore, Inc. Key Details

US$26.5m

Revenue

US$3.9m

Cost of Revenue

US$22.5m

Gross Profit

US$34.8m

Other Expenses

-US$12.2m

Earnings

Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 06, 2025
Earnings per share (EPS)
-1.64
Gross Margin
85.22%
Net Profit Margin
-46.24%
Debt/Equity Ratio
0%

electroCore, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

About ECOR

Founded
2005
Employees
73
CEO
Daniel Goldberger
WebsiteView website
www.electrocore.com

electroCore, Inc., a bioelectronic medicine and general wellness company, provides non-invasive vagus nerve stimulation (“nVNS”) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an, app-enabled general wellness product. It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions. In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

U.S. Market Performance

  • 7 Days: -1.2%
  • 3 Months: 13.1%
  • 1 Year: 22.8%
  • Year to Date: 7.3%
Over the last 7 days, the market has dropped 1.2%, driven by a decline of 4.7% in the Consumer Discretionary sector. In contrast to the last week, the market is actually up 23% over the past year. Earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading